Darwin Wealth Management LLC Trims Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Darwin Wealth Management LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN) by 7.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 722 shares of the medical research company’s stock after selling 59 shares during the quarter. Darwin Wealth Management LLC’s holdings in Amgen were worth $208,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Delos Wealth Advisors LLC increased its holdings in Amgen by 2,500.0% during the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares during the period. Catalyst Financial Partners LLC increased its holdings in Amgen by 3.8% during the 4th quarter. Catalyst Financial Partners LLC now owns 2,153 shares of the medical research company’s stock worth $620,000 after purchasing an additional 79 shares during the period. Clearwater Capital Advisors LLC increased its holdings in Amgen by 3.8% during the 4th quarter. Clearwater Capital Advisors LLC now owns 1,872 shares of the medical research company’s stock worth $539,000 after purchasing an additional 69 shares during the period. Pinnacle Wealth Management Advisory Group LLC increased its holdings in Amgen by 1.8% during the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 13,104 shares of the medical research company’s stock worth $3,774,000 after purchasing an additional 238 shares during the period. Finally, National Pension Service boosted its position in Amgen by 2.0% during the 4th quarter. National Pension Service now owns 897,035 shares of the medical research company’s stock valued at $258,364,000 after acquiring an additional 17,831 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Performance

Shares of NASDAQ AMGN traded up $5.55 during trading on Thursday, reaching $312.86. 2,920,928 shares of the company traded hands, compared to its average volume of 2,909,855. The firm’s fifty day simple moving average is $276.24 and its 200 day simple moving average is $281.92. The stock has a market cap of $167.83 billion, a P/E ratio of 44.69, a PEG ratio of 3.00 and a beta of 0.60. Amgen Inc. has a 12-month low of $211.71 and a 12-month high of $329.72. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.76 by $0.20. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The firm had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.45 billion. During the same quarter in the previous year, the business earned $3.98 EPS. Amgen’s revenue for the quarter was up 22.0% compared to the same quarter last year. As a group, research analysts anticipate that Amgen Inc. will post 19.46 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be paid a $2.25 dividend. The ex-dividend date is Thursday, May 16th. This represents a $9.00 annualized dividend and a dividend yield of 2.88%. Amgen’s dividend payout ratio is presently 128.57%.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 2,117 shares of Amgen stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total value of $662,811.53. Following the completion of the transaction, the senior vice president now owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.69% of the stock is owned by company insiders.

Analyst Ratings Changes

AMGN has been the topic of several recent research reports. Oppenheimer reaffirmed an “outperform” rating and set a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. Truist Financial reaffirmed a “buy” rating and set a $320.00 target price on shares of Amgen in a research report on Friday, April 12th. Morgan Stanley increased their target price on Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a research report on Friday, May 3rd. Leerink Partnrs cut Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Finally, Raymond James started coverage on Amgen in a research report on Thursday, March 28th. They issued a “market perform” rating for the company. Ten investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $305.65.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.